Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
View Patent ↗Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
1. Crystalline Compound (I):
which has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3±0.2° 2θ.
2. The crystalline compound (I) of claim 1 , wherein the crystalline compound comprises less than 10% by weight of any other crystalline Compound (I).
3. The crystalline compound (I) of claim 2 , wherein the crystalline compound (I) comprises less than 5% by weight of any other crystalline Compound (I).
4. The crystalline compound (I) of claim 1 , wherein the crystalline compound comprises less than 10% by weight of amorphous Compound (I).
5. The crystalline compound (I) of claim 4 , wherein the crystalline compound (I) comprises less than 5% by weight of amorphous Compound (I).
6. The crystalline compound (I) of claim 1 , which has a DSC endotherm at about 175.8° C.
7. The crystalline compound (I) of claim 1 , wherein the crystalline compound (I) comprises less than 100 ppm of a compound of Formula (II),
as determined by GC/MS.
8. The crystalline compound (I) of claim 7 , wherein the crystalline compound (I) comprises less than 50 ppm of a compound of Formula (II).
9. The crystalline compound (I) of claim 8 , wherein the crystalline compound (I) comprises less than 10 ppm of a compound of Formula (II).
10. The crystalline Compound (I) of claim 1 , wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
11. A pharmaceutical composition comprising the crystalline compound (I) of claim 1 .
12. An oral dosage form comprising the crystalline compound (I) of claim 1 .
13. Crystalline Compound (I),
which has an X-ray powder diffraction pattern as shown in FIG. 1 .
14. A pharmaceutical composition comprising the crystalline compound (I) of claim 13 .
15. Crystalline Compound (I),
prepared by crystallization from a solution comprising acetone and Compound (I).
16. The crystalline compound (I) of claim 15 , which has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3±0.2° 2θ.
17. The crystalline compound (I) of claim 16 , which has a DSC endotherm at about 175.8° C.
18. A pharmaceutical composition comprising the crystalline compound (I) of claim 15 .
19. A pharmaceutical composition comprising the crystalline compound (I) of claim 7 .
20. A pharmaceutical composition comprising the crystalline compound (I) of claim 10 .